Manufacturing DTaP-based combination vaccines: industrial challenges around essential public health tools

References

• Ramon G. Notice des titres et travaux scientifiques de G. Ramon. Paris: Ancienne imprimerie de la Cour d’Appel; 1934. p. 109.
   Google Scholar
• Parkman PD. Combined and simultaneously administered vaccines. A brief history. Ann N Y Acad Sci. 1995;754:1–9.
   PubMed Web of Science ®Google Scholar
• Shulman ST, Yogev R, Block SL, et al. History and development of Haemophilus Influenzae type B vaccine. Pediatr Ann. 2012;41:38–39.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Ward J, Shouval D, et al. Hepatitis B vaccines. In: Plotkin SA, Orenstein WA, Offit P, et al., editors. Vaccines. 6th ed. New York (NY): Elsevier Saunders; 2013. p. 205–234. Chapter 15.
   Google Scholar
• Pierce VM, Vázquez M. New combination vaccines: integration into pediatric practice. Pediatr Infect Dis J. 2007;26:1149–1150.
   PubMed Web of Science ®Google Scholar
• Pines E, Barrand M, Fabre P, et al. New acellular pertussis-containing paediatric combined vaccines. Vaccine. 1999;17:1650–1656.
   PubMed Web of Science ®Google Scholar
• Choo S, Finn A. Pediatric combination vaccines. Curr Opin Pediatr. 1999;11:14–20.
   PubMedGoogle Scholar
• Decker MD, Edwards K, Bogaerts HH. Combination vaccines. In Plotkin SA, Orenstein WA, Offit P, editors. Vaccines. 6th ed. New York (NY): Elsevier Saunders; 2012. p. 981–1007.
   Google Scholar
• Marcy SM. Pediatric combination vaccines: their impact on patients, providers, managed care organizations, and manufacturers. Am J Manag Care. 2003;9:314–320.
   PubMed Web of Science ®Google Scholar
• Behzad B, Jacobson SH, Sewell EC. Pricing strategies for combination pediatric vaccines based on the lowest overall cost formulary. Expert Rev Vaccines. 2012;11:1189–1197.
   PubMed Web of Science ®Google Scholar
• Peny JM, Gleizes O, Covilard JP. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective. Vaccine. 2005;23:4610–4618.
   PubMed Web of Science ®Google Scholar
• Szucs TD. Health economic research on vaccinations and immunisation practices–an introductory primer. Vaccine. 2005;23:2095–2103.
   PubMed Web of Science ®Google Scholar
• Esposito S, Tagliabue C, Bosis S, et al. Hexavalent vaccines for immunization in paediatric age. Clin Microbiol Infect. 2014;20(Suppl 5):76–85.
   PubMed Web of Science ®Google Scholar
• Carollo M, Palazzo R, Bianco M, et al. Hepatitis B specific T cell immunity induced by primary vaccination persists independently of the protective serum antibody level. Vaccine. 2013;31:506–513.
   PubMed Web of Science ®Google Scholar
• Sahoo N, Choudhury K, Manchikanti P. Manufacturing of biodrugs. Biodrugs. 2009;23:217–229.
   PubMed Web of Science ®Google Scholar
• O’Donnell K, Greene A, Zwitkovits M, et al. Quality risk management: putting GMP controls first. J Pharm Science Technol. 2012;66:243–261.
   Google Scholar
• WHO Expert Committee on Specifications for Pharmaceutical Preparations. WHO good manufacturing practices for pharmaceutical products: main principles. WHO Technical Report Series No. 961, forty-fifth report, Annex 3. Geneva: World Health Organization; 2011.
   Google Scholar
• WHO Expert Committee on Biological Standardization. WHO good manufacturing practices for biological products. WHO Technical Report Series No. 822, forty-second report, Annex 1. Geneva: World Health Organization; 1992.
   Google Scholar
• Milstein J, Costa A, Jadhav S, et al. Reaching international GMP standards for vaccine production: challenges for developing countries. Expert Rev Vaccines. 2009;8:559–566.
   PubMed Web of Science ®Google Scholar
• Speck D. Specific aspects of vaccine manufacturing. Ann Pharm Fr. 2009;67:213–218.
   PubMedGoogle Scholar
• Soubeyrand B, Gerdil E. Développement et approvisionnement des vaccins: un point de vue de l’industrie. In: Gaudelus J, editor. Vaccinologie. Paris: 2007.
   Google Scholar
• Monahan TR. Vaccine industry perspective of current issues of good manufacturing practices regarding product inspections and stability testing. Clin Infect Dis. 2001;33(Suppl 4):S356–S361.
   PubMed Web of Science ®Google Scholar
• Falk LA, Arciniega J, McVittie L. Manufacturing issues with combining different antigens: a regulatory perspective. Clin Infect Dis. 2001;33(Suppl 4):S351–S355.
   PubMed Web of Science ®Google Scholar
• Gomez PL, Robinson JM, Rogalewicz JA. Vaccine manufacturing. In: Plotkin SA, Orenstein WA, Offit P, editors. Vaccines. 6th ed. Orlando: WB Saunders Company; 2013. p. 44–57.
   Google Scholar
• Van Hoof J. Manufacturing issues related to combining different antigens: an industry perspective. Clin Infect Dis. 2001;33(Suppl 4):S346–S350.
   PubMed Web of Science ®Google Scholar
• Gerson D. 2015. “Vaccine manufacturing - part 1 of 2”, in The Biomedical & Life Sciences Collection, Henry Stewart Talks Ltd, London. [cited 2016 Jun 8]. Available from: https://hstalks.com/bs/3053/
   Google Scholar
• Gerson D. 2015. “Vaccine manufacturing - part 2 of 2”, in The Biomedical & Life Sciences Collection, Henry Stewart Talks Ltd, London [cited 2016 Jun 8]. Available from: https://hstalks.com/bs/3054/
   Google Scholar
• Kenakin T, Williams M. Defining and characterizing drug/compound function. Biochem Pharmacol. 2014;87:40–63.
   PubMed Web of Science ®Google Scholar
• Marichal-Gallardo PA, Alvarez MM. State-of-the-art in downstream processing of monoclonal antibodies: process trends in design and validation. Biotechnol Prog. 2012;28:899–916.
   PubMed Web of Science ®Google Scholar
• Colombo S, Zeng X, Ragelle H, et al. Complexity in the therapeutic delivery of RNAi medicines: an analytical challenge. Expert Opin Drug Deliv. 2014;11:1481–1495.
   PubMed Web of Science ®Google Scholar
• Patel KT, Chotai NP. Pharmaceutical GMP: past, present, and future–a review. Pharmazie. 2008;63:251–255.
   PubMed Web of Science ®Google Scholar
• Brito LA, Malyala P, O’Hagan DT. Vaccine adjuvant formulations: a pharmaceutical perspective. Semin Immunol. 2013;25:130–145.
   PubMed Web of Science ®Google Scholar
• Matheis W, Zott A, Schwanig M. The role of the adsorption process for production and control combined adsorbed vaccines. Vaccine. 2002;20:67–73.
   Web of Science ®Google Scholar
• Lindblad EB. Aluminium coumpounds for use in vaccines. Immunol Cell Biol. 2004;82:497–505.
   PubMed Web of Science ®Google Scholar
• Shi Y, HogenEsch H, Regnier FE, et al. Detoxification of endotoxin by aluminium hydroxide adjuvant. Vaccine. 2001;19:1747–1752.
   PubMed Web of Science ®Google Scholar
• Schlegl R, Weber M, Wruss J, et al. Influence of elemental impurities in aluminium hydroxide adjuvant on the stability of inactivated Japanese Encephalitis vaccine, IXIARO. Vaccine. 2015;33:5989–5996.
   PubMed Web of Science ®Google Scholar
• Sturgess AW, Rush K, Charbonneau RJ, et al. Haemophilus influenzae type b conjugate vaccine stability: catalytic depolymerization of PRP in the presence of aluminum hydroxide. Vaccine. 1999;17:1169–1178.
   PubMed Web of Science ®Google Scholar
• Cintra FDO, Takagi M. Study of the chemical stability of the capsular polysaccharide produced by Haemophilus influenzae type b. Carbohydr Polym. 2015;116:167–172.
   PubMed Web of Science ®Google Scholar
• Hansen B, Sokolovska A, HogenEsch H, et al. Relationship between the strength of antigen adsorption to an aluminium-containing adjuvant and the immune response. Vaccine. 2007;25:6618–6627.
   PubMed Web of Science ®Google Scholar
• Hem SL, HogenEsch H. Relationship between physical and chemical properties of aluminium-containing adjuvants and immunopotentiation. Expert Rev Vaccines. 2007;6:685–698.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for independent lot release of vaccines by regulatory authorities. WHO Experts Committee on Biological Standardization. Sixty-first report. Geneva: WHO; 2012. Annex 2, WHO Technical Report Series, no. 978.
   Google Scholar
• World Health Organization. Recommendations to assure the quality, safety and efficacy of diphtheria vaccines (adsorbed). Replacement of annex 2 of WHO technical report series, no. 800, and annex 5 of WHO technical report series, no. 927. WHO Experts Committee on Biological Standardization. Sixty-third report. Geneva: WHO; 2014. Annex 4, WHO Technical Report Series, no. 980.
   Google Scholar
• World Health Organization. Recommendations to assure the quality, safety and efficacy of tetanus vaccines (adsorbed). Replacement of annex 2 of WHO technical report series, no. 800, and annex 5 of WHO technical report series, no. 927. WHO Experts Committee on Biological Standardization. Sixty-third report. Geneva: WHO; 2014. Annex 5, WHO Technical Report Series, no. 980.
   Google Scholar
• World Health Organization. Recommendations to assure the quality, safety and efficacy of acellular pertussis vaccines replacement of annex 2 of WHO technical report series, no. 878. WHO Experts Committee on Biological Standardization. Sixty-second report. Geneva: WHO; 2013. Annex 4, WHO Technical Report Series, no. 979.
   Google Scholar
• World Health Organization. Recommendations to assure the quality, safety and efficacy of poliomyelitis vaccines (inactivated). Replacement of annex 2 of WHO technical report series, no. 910. WHO Experts Committee on Biological Standardization. Sixty-fifth report. Geneva: WHO; 2015. Annex 3, WHO Technical Report Series, no. 993.
   Google Scholar
• World Health Organization. Recommendations for the production and control of Haemophilus influenzae type b conjugate vaccines. WHO Experts committee on biological standardization. Forty-ninth report. Geneva: WHO; 2000. Annex 1, WHO Technical Report Series, no. 897.
   Google Scholar
• World Health Organization. Recommendations to assure the quality, safety and efficacy of recombinant hepatitis B vaccines. Replacement of annex 2 of WHO technical report series, no. 786 and annex 4 of WHO technical report series, no. 889. WHO Experts Committee on Biological Standardization. Sixty-first report. Geneva: WHO; 2012. Annex 4, WHO Technical Report Series, no. 978.
   Google Scholar
• Xing D, Asokanathan C, Xu TH, et al. Relationship of immunogenicity to protective potency in acellular pertussis vaccines. Hum Vaccin Immunother. 2014;10:2066–2073.
   PubMed Web of Science ®Google Scholar
• Mittag HJ, Horst Rinne H. Statistical methods of quality assurance. New York (NY): CRC Press; 1993. p. 664.
   Google Scholar
• Gupta RK, Gupta CK, Mallet L. Lot release of vaccines by regulatory authorities and harmonization of testing requirements. In: Nunnaly BK, Turula V, Sitrin R, editors. Vaccine analysis: strategies, principles, and control. Berlin: springer-Verlag; 2015. p. 573–596.
   Google Scholar
• Metz B, Dobbelsteen Van Den G, Els Van C, et al. Quality-control issues and approaches in vaccine development. Expert Rev Vaccines. 2009;8:227–238.
   PubMed Web of Science ®Google Scholar
• Radzihovsky J, Schiller CD, Gleixner R, et al. 2015. Post-Approval Change Management On a Global Scale: an Inconvenient Complexity for Pharma? Scrip Regulatory Affairs. [cited 2016 Jun 8]. Available from: http://www.rajpharma.com/productsector/pharmaceuticals/Post-Approval-Change-Management-On-A-Global-Scale-An-Inconvenient-Complexity-For-Pharma-361629?autnID=/contentstore/rajpharma/codex/bf7e9076-8eac-11e5-aa60-dfe81e3cf02a.xml
   Google Scholar
• WHO. Polio vaccines: WHO position paper - March, 2016. Vol. 91, WER. Geneva: WHO; 2016. p. 145–168.
   Google Scholar
• Campbell PT, McCaw JM, McIntyre P, et al. Defining long-term drivers of pertussis resurgence, and optimal vaccine control strategies. Vaccine. 2015;33:5794–5800.
   PubMed Web of Science ®Google Scholar
• Mendivil S, Bloomfield J, Anicetti V, et al. Parenteral drug association points to consider: pharmaceutical quality metrics updated September 2014. PDA J Pharm Sci and Tech. 2014;68:535–545.
   PubMedGoogle Scholar
• Magnani J, Vinther A. Can quality solve the equation? ↓pricing + ↑health authority expectations + ↑ supply chain complexity + ↑ counterfeiting = quality drugs to patients + an engaged workforce. PDA J Pharm Sci and Tech. 2012;66:518–525.
   PubMedGoogle Scholar